Lutris Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Lutris Pharma's estimated annual revenue is currently $775k per year.
- Lutris Pharma's estimated revenue per employee is $155,000
Employee Data
- Lutris Pharma has 5 Employees.
- Lutris Pharma grew their employee count by 0% last year.
Lutris Pharma's People
Name | Title | Email/Phone |
---|
Lutris Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $2.8M | 18 | -10% | $43M | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $6M | 39 | 5% | $23.4M | N/A |
#4 | $8.1M | 52 | 27% | $12.5M | N/A |
#5 | $1.6M | 10 | 0% | N/A | N/A |
#6 | $3.6M | 23 | 5% | $8.44M | N/A |
#7 | $5.3M | 34 | 0% | N/A | N/A |
#8 | $2.8M | 18 | 38% | $6.1M | N/A |
#9 | $9.3M | 60 | 40% | $22M | N/A |
#10 | $5.3M | 28 | 56% | N/A | N/A |
What Is Lutris Pharma?
Lutris Pharma is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance. The company aims to provide novel topical therapies in order to mitigate these side effects. Lutris Pharma’s lead asset, LUT014, a topical B-Raf Inhibitor, is a proprietary, first-in-class, small molecule currently in a phase 2 clinical trial in metastatic colorectal cancer patients with EGFR inhibitor induced acneiform lesions and a phase 1/2 study for the treatment of radiation-induced dermatitis.
keywords:N/AN/A
Total Funding
5
Number of Employees
$775k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 5 | -44% | N/A |
#2 | $0.4M | 5 | 0% | N/A |
#3 | $1.3M | 5 | -17% | N/A |
#4 | $0.6M | 5 | -29% | N/A |
#5 | $0.7M | 5 | 67% | N/A |